Vaccine problems persist in Europe as Spain and Italy have stopped using AstraZeneca for people under their 60s


Spain and Italy have limited the use of the AstraZeneca COVID-19 vaccine for people over the age of 60, which could slow down the European Union’s slow immunization program, which is lagging behind countries such as the United States, the United Kingdom and Israel.

The two countries made the decision on Wednesday after the European Medicines Agency (EMA) said it had found Possible link Among the pharmaceutical company AstraZeneca
+ 2.52%

+ 2.07%

Vaccine and very rare cases of blood clotting problems in adults. The EMA recommended that there be no age restrictions, as it stressed that the benefits of the shot outweigh the risks.

Read: Regulators in the European Union and the United Kingdom say AstraZeneca is safe, but an alternative dose will be offered to Brits under the age of 30

The Italian Ministry of Health recommended that the vaccine only be used for people over the age of 60, but it said that those under the age of 60 who have already received the first dose of AstraZeneca can also take a second dose.

Last month, the French and German health officials Restriction of AstraZeneca injection to those over 55 and over 60, respectively, after concerns about unusual blood clots in some recipients.

Earlier on Wednesday, the United Kingdom’s Joint Commission on Vaccination and Immunization (JCVI) changed its guidelines on vaccination, recommending people Less than 30 Get alternate shots, such as the one jointly developed by BioNTech
+ 0.55%

And the pharmaceutical company Pfizer
+ 0.19%
Or moderna biotechnology
+ 1.59%

First, because of the rare “fading” side effect of blood clots in the brain.

Read: United States government to study allergic reactions to COVID-19 vaccines

Shares in AstraZeneca were up 2.04% in morning London trade on Thursday. Stocks are down less than 1% in the year so far, according to data from FactSet.

Spain and Italy’s decision to restrict syringe use could make it difficult for the European Union to achieve its goal of vaccination 70% Of its adult population by the end of summer.

The 27-member bloc has already failed to reach its first stage of receiving at least 80% of people over 80 and 80% of healthcare workers against COVID-19 by the end of March, according to the latest data from European Center for Disease Prevention and Control.

The frequency of vaccinations may pick up later this month when the Johnson & Johnson Pharmaceutical Company begins

Delivery of the single-shot COVID-19 vaccine to the European Union begins. The block signed a confirmed order for 200 million J&J doses and an option for another 200 million doses.

Read: Oxford discontinues AstraZeneca COVID vaccine trial in children and adolescents due to blood clotting problem

On Wednesday, AstraZeneca acknowledged results from EMA and UK Medicines and Healthcare Products Regulatory Agency, Noting that both reviews “confirmed again that the vaccine provides a high level of protection against all the severity of COVID-19 and that these benefits still far outweigh the risks.”

The British-Swedish pharmaceutical company said it is working with global regulators to better understand individual cases, epidemiology and potential mechanisms that could explain these extremely rare events.

Separately on wednesday, World Health Organization The Vaccine Safety Advisory Committee said that although the blood clot connection was “reasonable” it was “not confirmed”, and cases were “very rare” among the 200 million people vaccinated with AstraZeneca globally.

More to track …
Bulletin Observer Business News

[Advertisement Plan]

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Translate »